imatinib / Generic mfg. - LARVOL DELTA

Ileal Gastrointestinal Stromal Tumor Presenting With Subacute Intestinal Obstruction and Synchronous Peritoneal Metastases: A Case Report. (PubMed, Cureus) - "The postoperative course was uneventful, and imatinib 400 mg daily was started one week later. After nearly two years of clinical and radiological follow-up, the patient remained stable without disease progression. This report highlights that ileal GIST should be considered in cases of unexplained small bowel obstruction, especially when imaging shows an exophytic mass without lymphadenopathy."

Journal • Constipation • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Hematological Disorders • Hepatology • Oncology • Pain • Sarcoma • Small Intestinal Carcinoma • ANO1 • KIT

Precision therapeutic strategies for advanced gastrointestinal stromal tumors. (PubMed, Cancer Metastasis Rev) - "Imatinib, followed by later-line tyrosine kinase inhibitors, including sunitinib, regorafenib, ripretinib, and genotype-selected avapritinib, have substantially prolonged survival. In this review, we summarize the biological and molecular landscape of advanced GIST, as well as the current therapeutic strategies and major mechanisms of resistance. Finally, we highlight promising therapeutic strategies supported by preclinical and clinical evidence that may advance subtype-informed precision medicine."

Journal • Review • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • KIT • PDGFRA

SUBCUTANEOUS BLINATUMOMAB FOR PATIENTS WITH RELAPSED/REFRACTORY PHILADELPHIA CHROMOSOME–POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS FROM A PHASE 1/2 STUDY (EHA 2026) - P1/2 | "Eight patients (50%) received a TKI concurrently with SC blinatumomab (250/500: ponatinib, n=4; dasatinib, n=1; imatinib, n=1; 500/1000: ponatinib, n=2) with no new safety signals observed. These data support further evaluation of SC blinatumomab across Ph+ B-ALL settings. B-ALL, B-cell acute lymphoblastic leukemia; CR, complete remission; CRh, complete remission with partial hematologic recovery; CRi, complete remission with incomplete hematologic recovery; HSCT, hematopoietic stem cell transplantation; IP, investigational product; Ph+, Philadelphia chromosome–positive; R/R, relapsed or refractory; SC, subcutaneous; TIW, thrice weekly; TKI, tyrosine kinase inhibitor; QD, once daily"

Clinical • P1/2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Ischemic stroke • Leukemia • Septic Shock

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients (ASH 2025) - "Compared to the GIMEMA LAL2116 trial, anincrease in MRD negativity and less relapses were observed. A chemo-free approach should be the newstandard for adult Ph+ ALL."

Clinical • IO biomarker • P3 data • Acute Lymphocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myocardial Infarction • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • ABL1 • IKZF1

Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study (ASH 2025) - P2 | "Moreover, the bispecific T-cell engager blinatumomab (BLIN) hasemerged as a potent front-line modality in Ph+ALL. In older pts with Ph+ALL receiving upfront reduced-intensity chemotherapy (EWALL), PONinduces a higher, albeit not significant, deep molecular response rate compared to IM, The safety profileof PON was consistent with known AEs and did not lead to a higher rate of withdrawals from studytreatment than IM. The impact on survival will require longer follow-up."

Clinical • Combination therapy • Acute Lymphocytic Leukemia • Hypertension • Pancreatitis • Thrombosis • ABL1 • BCR

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) yields durable remissions and survival in adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL): Long-term follow-up of a prospective trial (ASH 2025) - P2 | "In a single-arm Phase II trial weconducted, DA-EPOCH ± rituximab (R) ± TKI yielded comparable morphologic (morph) and measurableresidual disease (MRD)- remissions with less toxicity than seen in a comparable cohort of patientsreceiving hyperCVAD. This study completed accrual in 2021, before routine upfront incorporation ofimmunotherapy and ponatinib (if Ph+)...Imatinib or dasatinib was added if Ph+, and R if CD20+...8 pts (15%) switched to blinatumomab whenMRD+ after DA-EPOCH, with none receiving it when MRD-. DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL... DA-EPOCH±R±TKI yields durable remissions, with survival comparable toimmunotherapy-based strategies for ALL. Unlike many other approaches, outcomes for older pts weresimilar to the general study population. These results support DA-EPOCH±R±TKI as a curative-intentoption, particularly in resource-limited settings."

Clinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • ABL1 • CD20

A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults (ASH 2023) - P1 | "Both patients with imatinib-refractory CML-LBC progressed (C9, C3). Of those with ALL, 8 bridged to SCT after 2-8 cycles; 2 elected local care (C5, C7); 1 transitioned to ponatinib for inadequate response plus recurrent DAS pulmonary toxicity (C4); 6 remained on study treatment until disease progression (C4 – MRD+, C45, C11, C11); 3 remain on study... Dual ABL1 kinase inhibition with ASC and DAS plus pred in BCR::ABL1+ ALL and CML-LBC is feasible and tolerable in adults with BCR::ABL1+ ALL and CML-LBC. DLTs at ASC 160 mg/d were asymptomatic amylase and lipase elevation, without clinical sequelae. ASC 80 mg/day was declared the RP2D, and an expansion cohort of 10 pts was completed."

Clinical • Combination therapy • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Chronic Myeloid Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology • Pancreatitis • ABL1 • BCR

Treatment of Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia in a Patient With Li-Fraumeni Syndrome (SOHO 2026) - "Treatment followed a chemotherapy-sparing approach modeled on the Foà/D-ALBA regimen: steroid prephase, dasatinib plus blinatumomab induction, and intrathecal methotrexate and hydrocortisone for CNS prophylaxis...At month 4, dasatinib was discontinued due to a left pleural effusion and replaced with asciminib (off-label use); ponatinib was avoided given the effusion history, and imatinib was felt to offer insufficient potency... To our knowledge, this is the first reported case of Ph+ B-cell ALL in a patient with LFS. It illustrates that a chemotherapy-sparing TKI-bispecific backbone, with substitution of asciminib for dasatinib intolerance, can achieve deep molecular remission while limiting genotoxic exposure in this high-risk population. ALL: acute lymphoblastic leukemia, BCR-ABL1: breakpoint cluster region–Abelson murine leukemia viral oncogene homolog 1, CAR-T: chimeric antigen receptor T-cell, CD: cluster of differentiation, CNS: central nervous system, FISH:..."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

Comparative Efficacy and Safety of Front-line Regimens for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Network Meta-Analysis (SOHO 2026) - " We searched PubMed, Embase, and 2024–2026 conference abstracts for prospective trials of frontline TKIs (imatinib, dasatinib, ponatinib) with chemotherapy or blinatumomab. Ponatinib plus blinatumomab is the most effective front-line regimen for Ph–positive ALL, offering superior molecular depth and survival. These findings support chemotherapyfree protocols as the new standard of care and suggest that deep molecular responses may safely allow the omission of front-line SCT. CMR: complete molecular response, CrI: credible interval, EFS: event-free survival, HR: hazard ratio, hyper-CVAD: cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, MRD: measurable residual disease, OS: overall survival, SCT: stem cell transplant, SUCRA: surface under the cumulative ranking curve."

Retrospective data • Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Modifiable determinants of adherence to tyrosine kinase inhibitors in classical myeloproliferative neoplasms: A mixed-methods systematic review protocol. (PubMed, PLoS One) - "This review will provide a theory-informed synthesis of modifiable determinants of TKI adherence in classical MPNs, supporting the identification of targets for future adherence-enhancing interventions."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • ABL1

IGF2-associated tumor cells and APOE-positive macrophages define an imatinib resistance-associated niche in gastrointestinal stromal tumors. (PubMed, Gastric Cancer) - "These findings reveal distinct tumor-cell-macrophage niches underlying imatinib sensitivity and resistance in GIST, and identify the IGF2-associated GIST tumor-cell state-APOE-positive TAM axis as a candidate resistance-associated tumor-immune state with potential biomarker and therapeutic implications."

Journal • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • APOE • IGF2 • S100A6

Pulmonary Tumor Thrombotic Microangiopathy: A Systematic Review of Case Reports (ERS 2026) - "Imatinib and bevacizumab showed potential efficacy. In summary, our analysis of PTTM cases reveals a strong association with East Asia, gastric/breast/lung malignancy, and adenocarcinoma. Its high mortality underscores the urgent need for early recognition and more effective therapies."

Case report • Clinical • Review • Breast Cancer • Cardiovascular • Lung Adenocarcinoma • Lung Cancer • Oncology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

PDGF pathway: tyrosine kinase inhibitors (ERS 2026) - "More recently, there has been renewed interest in this group of medications, prompted by the development of inhaled seralutinib together with further study of imatinib. This presentation will review the pleotropic effects of TKIs in PAH and the evidence supporting the use of selected TKIs in PAH."

Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Post-Hoc Long-Read Sequencing Links Leukemic Mutation Status to Single-Cell Transcriptomes. (PubMed, Eur J Haematol) - "In primary chronic myeloid leukemia samples, the post hoc approach detected BCR::ABL1-positive cells at diagnosis, but not during imatinib treatment. Together, we present a framework for adding mutation status to cells already profiled using the 10X Genomics workflow and highlight broader considerations for transcript-based single-cell genotyping."

Journal • Retrospective data • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • ABL1

Adjuvant therapy for resectable gastrointestinal stromal tumors: evidence, controversies, and practical guidance. (PubMed, Expert Rev Anticancer Ther) - "Adjuvant imatinib should be individualized using validated clinicopathologic risk models plus molecular testing. Key unresolved issues include optimal duration for the highest-risk subsets, the role and dose of adjuvant therapy for KIT exon 9 tumors, and adjuvant strategies for imatinib-resistant genotypes."

Journal • Review • Gastrointestinal Stromal Tumor • Oncology • Sarcoma

A Case of Giant Exophytic Gastric GIST Presenting with the Torricelli-Bernoulli Sign during Regorafenib Treatment (PubMed, Gan To Kagaku Ryoho) - "Imatinib and sunitinib were administered; however, the tumor was refractory. However, in this case, it is believed that structural destruction of the gastric wall resulted from tumor enlargement owing to drug resistance, thereby leading to the presence of gas. Therefore, we report this case as this course of events was highly informative to our understanding of the process of GIST perforation."

Journal • Colorectal Cancer • Gastric Cancer • Oncology • Rectal Cancer • Solid Tumor

The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study. (PubMed, J Gastrointest Oncol) - "The deletion and indel mutations of KIT exon 11 may be unfavorable prognostic factors for patients with GIST. Prolongation of adjuvant imatinib treatment to 5 years may provide greater benefit to patients with high-risk GISTs harboring KIT exon 11 mutations."

Journal • Retrospective data • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • KIT

Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST). (ASCO-GI 2025) - P3 | "Funded by Cogent Biosciences Clinical Trial Registration Number: NCT05208047 Background: After initial response to first line therapy with imatinib, GISTs commonly progress due to secondary resistance mutations in KIT. Data from Peak Part 1 show an encouraging safety and tolerability profile generally consistent with published sunitinib monotherapy experience. ORR in evaluable pts from Part 1 was 20%; ORR in 2nd line pts was 33%. Part 2 of the Peak study is actively enrolling pts globally at the selected dose of bezuclastinib 600 mg QD + sunitinib 37.5 mg QD versus sunitinib 37.5 mg QD."

Clinical • P3 data • Stroma • Gastrointestinal Cancer • Oncology • KIT

Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study (Sarcoma-RC 2024) - P3 | "In this randomized study, matinib interruption in non-progressing GIST patients was associated with faster resistance to imatinib and shorter OS in the long-term."

Clinical • Metastases • Oncology

Primary results of the phase 3 peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST). (ASCO 2026) - P3 | "The Peak study evaluated efficacy and safety of bezuclastinib + sunitinib vs standard second-line sunitinib monotherapy in patients with advanced GIST who received prior imatinib therapy. Combined KIT inhibition with bezuclastinib + sunitinib significantly improved mPFS vs sunitinib monotherapy, reducing the risk of progression or death by 50% and increasing ORR from 26% to 46%. The combination was well tolerated with no new safety findings."

Metastases • Monotherapy • P3 data • Stroma • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Neutropenia • Oncology • Sarcoma

Personalized N-of-1 Combination Therapies for Advanced Gastrointestinal Stromal Tumors. (PubMed, JCO Precis Oncol) - P=N/A | "Our results demonstrate that a multitargeted, biomarker-matched combination approach can be safely administered to obtain disease control. Tailored combination therapies for advanced GIST with multiple genomic alterations warrant further investigation."

Journal • Retrospective data • Cardiovascular • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Hypertension • Oncology • Sarcoma • CDKN2A • CDKN2B • KIT

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. (PubMed, J Clin Oncol) - P3 | "Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib."

Journal • P3 data • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • Solid Tumor

Impact of Posterior Reversible Encephalopathy Syndrome on Hospitalization and Mortality in Tyrosine Kinase Inhibitor-Treated Patients With Hematologic Malignancies: A Real-World Propensity-Matched Analysis (SOHO 2026) - " Using the TriNetX Global Collaborative Network (170 healthcare organizations), we identified TKI-treated patients (imatinib, dasatinib, bosutinib, ibrutinib, or erlotinib) who developed PRES within 1 year of initiation (cohort 1, n = 135) vs TKI-treated controls without PRES (cohort 2, n = 69764), excluding those with cocaine use disorders or hypertensive urgency/emergency. TKI-treated patients, including those receiving CML-directed BCR-ABL1 inhibitors, who developed PRES faced a nearly 2-fold increased hazard of hospitalization (HR, 1.799) and nearly 3-fold increased hazard of death (HR, 2.683) compared to propensity-matched controls, with median survival reduced to 1758 days versus not reached. PRES should be recognized as a high-stakes complication rather than a transient neurological event. Given the markedly shortened time to first hospitalization (190 vs 1404 days), early vigilance for PRES in TKI-treated patients is warranted."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCR

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial. (PubMed, Blood) - "The hazard ratio for time to discontinuation of treatment due to AEs for asciminib vs 2G TKIs was 0.46 (95% CI, 0.215%-0.997%). With longer follow-up, asciminib continued to demonstrate a favorable benefit-risk profile over IS-TKIs and imatinib, supporting its potential as a treatment option for newly diagnosed CML-CP."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting (ASH 2024) - P2 | "Ponatinib induction followed by imatinib consolidation induces high rates of MMR and DMR at M18, higher than that with TKI2 as front-line therapy as reported in the literature in CP-CML pts. Whether or not this translates into substantial TFR rates is yet to be determined."

Breast Cancer • Cardiovascular • Chronic Myeloid Leukemia • CNS Disorders • Diabetes • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Infectious Disease • Metabolic Disorders • Neutropenia • Osteoarthritis • Solid Tumor • Thrombosis • ABL1